Prognostic marker PTPN6 in glioma and its relationship with immune infiltration

Abstract

Background & Objective: Glioma is a type of malignant tumor that develops in the neurological system, and identification of glioma biomarkers is critical. PTPN6 is a protein tyrosine phosphatase. The role of PTPN6 in glioma is unclear. This is the first study to investigate the expression of PTPN6 in glioma patients and its prognostic value, potential biological functions, and impact on the immune system.

Methods: Gene expression and clinicopathological analysis, enrichment analysis, and immune infiltration analysis were based on The Cancer Genome Atlas (TCGA) data with additional bioinformatics analysis. Statistical analysis was performed using TIMER and ssGSEA to analyze the immune response to PTPN6 expression in glioma. In addition, CGGA, K-M survival analysis, and data from HPA were used to validate the results.

Results: PTPN6 played a vital role as an independent prognostic factor in glioma patients. PTPN6 expression correlated with age, WHO grade, IDH status and 1p/19q codeletion. GSEA found that PTPN6 is closely related to cell adhesion, immunological. PTPN6 expression was positively correlated with infiltration of B cells, CD8+ T cells, CD4+ T cells, macrophages, dendritic cells, and neutrophils and was co-expressed with immune-related genes and immune checkpoints.

Conclusion: The expression of PTPN6 is increased in gl666ioma, and the high expression of PTPN6 is associated with poor prognosis. PTPN6 may affect tumor development by regulating tumor-infiltrating cells in the tumor microenvironment (TME). PTPN6 may be a potential target for immunotherapy.